Alpha Synuclein S129A Mutant Monomers
CAT:
400-SPR-505C
Size:
2x 100 µg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: Yes












Alpha Synuclein S129A Mutant Monomers
Background:
Elevated levels of phosphoserine 129 (pS129) on alpha-synuclein has long been considered a hallmark of Parkinson’s disease and other synucleinopathies, where up to 90% of alpha-synuclein deposition in Lewy Bodies contains pS129, compared to ≤4% in normal brains (reviewed in [1]). Further, pS129 was recently shown to function as a physiological regulator of neuronal activity (2). Alpha-synuclein S129A monomers and fibrils cannot be phosphorylated at position 129, and therefore can be utilized to study phospho-S129-independent biology and pathology. Further, this material can be used to confirm induction of endogenous pS129 pathology in disease models.Description:
Human Recombinant Alpha Synuclein S129A Mutant MonomersProduct Name Alternative:
Alpha synuclein protein, Alpha-synuclein protein, Non-A beta component of AD amyloid protein, Non-A4 component of amyloid precursor protein, NACP protein, SNCA protein, NACP protein, PARK1 protein, SYN protein, Parkinson's disease familial 1 Protein, Alpha Synuclein S129AUNSPSC:
12352202Swiss Prot:
P37840-1Host:
E. coliOrigin Species:
HumanTarget:
Alpha Synuclein S129AConjugation:
No TagSequence:
MDVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGVVHGVATVAEKTKEQVTNVGGAVVTGVTAVAQKTVEGAGSIAAATGFVKKDQLGKNEEGAPQEGILEDMPVDPDNEAYEMPAEEGYQDYEPEAApplications:
WB, In vivo Assay, In vitro AssayPurification Method:
Ion-exchange PurifiedConcentration:
2 mg/mlPurity:
>95%Weight:
0.02Length:
Full length (1 - 140 aa)Buffer:
1X PBS pH7.4Molecular Weight:
14.44 kDaPrecautions:
Not for use in humans. Not for use in diagnostics or therapeutics. For research use only.Additionnal Information:
For corresponding PFFs, see catalog# SPR-506References & Citations:
1. Xu, Deng and Qing. 2015. The phosphorylation of α-synuclein: development and implication for the mechanism and therapy of the Parkinson's disease. Journal of Neurochemistry. https://doi.org/10.1111/jnc.13234 2. Ramalingam et al. 2023. Dynamic physiological α-synuclein S129 phosphorylation is driven by neuronal activity. NPJ Parkinsons Dis. doi: 10.1038/s41531-023-00444-w.
MSDS Document
View Document